IP Library Granted Patent US 7,176,233
Granted Patent B2
US 7,176,233 · App. 11/147,622 · Granted Feb 13, 2007

Salinosporamides and methods for use thereof

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,233
App. No.
11/147,622
Granted
Feb 13, 2007
Kind
B2
Abstract

The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC 50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

Claims (8)

1. A method of treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure (I):

wherein:

each of R 1 , R 2 , and R 3 is independently selected from a group consisting —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonamide or sulfuryl,

each R 4 is independently selected from a group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, and substituted cycloalkyl;

each of E 1 , E 2 , E 3 and E 4 is independently selected from a group consisting —O, —NR 5 , or —S, wherein R 5 is —H or C 1 –C 6 alkyl; and

x is an integer having the value between 0 and 8, thereby treating a mammalian cell proliferative disorder, wherein the disorder is characterized by the formation of a colorectal neoplasm.

2. The method of claim 1 , wherein the compound (I) has the structure:

3. The method of claim 1 , wherein the mammalian cell is human.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2016
From: HBM VIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCARDERO PARTNER II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 040327/0264 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jul 18, 2008
From: UNIVERSITY OF CALIFORNIA, SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021253/0588 →
Continuity (4)
Division 1083815700 · Apr 30, 2004
Continuation In Part 1060085400 · Jun 20, 2003
Provisional Application 6039131400 · Jun 24, 2002
Related Publication 20050239866A1 · Oct 27, 2005